Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants
- 315 Downloads
Anticoagulation therapy is a major risk factor for unfavorable patient outcomes following (traumatic) intracranial hemorrhage. Direct oral anticoagulants (DOAC) are increasingly used for the prevention and treatment of thromboembolic diseases. Data on patients treated for acute subdural hemorrhage (SDH) during anticoagulation therapy with DOAC are limited.
We analyzed the medical records of consecutive patients treated at our institution for acute SDH during anticoagulation therapy with DOAC or vitamin K antagonists (VKA) during a period of 30 months. Patient characteristics such as results of imaging and laboratory studies, treatment modalities and short-term patient outcomes were included.
A total of 128 patients with preadmission DOAC (n = 65) or VKA (n = 63) intake were compared. The overall 30-day mortality rate of this patient cohort was 27%, and it did not differ between patients with DOAC or VKA intake (26% vs. 27%; p = 1.000). Similarly, the rates of neurosurgical intervention (65%) and intracranial re-hemorrhage (18%) were comparable. Prothrombin complex concentrates were administered more frequently in patients with VKA intake than in patients with DOAC intake (90% vs. 58%; p < 0.0001). DOAC treatment in patients with acute SDH did not increase in-hospital and 30-day mortality rates compared to VKA treatment.
These findings support the favorable safety profile of DOAC in patients, even in the setting of intracranial hemorrhage. However, the availability of specific antidotes to DOAC may further improve the management of these patients.
KeywordsIntracranial hemorrhages Trauma Subdural hematoma Subdural hemorrhage Oral anticoagulants
We thank Nick Bornschein (Statworx, Frankfurt, Germany) for assistance with statistical analyses.
CB, SB, and AWU designed the study. CB, SB, and AY collected the data. CB, J-ON, and AWU analyzed the data and wrote the first draft of the manuscript. TR and JP analyzed the data and were major contributors in writing the manuscript. All authors read and approved the final manuscript.
Source of Support
There were no sources of funding received for this study.
Compliance with Ethical Standards
Conflict of interest
Christopher Beynon has received personal fees outside the submitted work from Bayer Healthcare, Boehringer Ingelheim, CSL Behring, and Tem International. Timolaos Rizos has received personal fees outside the submitted work from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo. For the remaining authors, no competing financial interests exist.
The study has been approved by the institutional review board. For this type of retrospective study, formal consent is not required.
- 1.Karni A, Holtzman R, Bass T, Zorman G, Carter L, Rodriguez L, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67:1098–100.Google Scholar
- 2.Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6–46.CrossRefGoogle Scholar
- 14.Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89:263–70.CrossRefGoogle Scholar
- 16.Pozzessere A, Grotts J, Kaminski S. Dabigatran use does not increase intracranial hemorrhage in traumatic geriatric falls when compared with warfarin. Am Surg. 2015;81:1039–42.Google Scholar
- 31.Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45:1304–12.CrossRefGoogle Scholar
- 38.Martin A-C, Le Bonniec B, Fischer A-M, Marchand-Leroux C, Gaussem P, Samama C-M, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168:4228–33.CrossRefGoogle Scholar
- 47.Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387:2605–13.CrossRefGoogle Scholar